Skip to main content

How does Ozempic affect blood pressure?

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 21, 2023.

Official answer

by Drugs.com

Ozempic (semaglutide) is more likely to lower blood pressure than to increase it and several trials of semaglutide have shown significant reductions in blood pressure in people who had normal blood pressure to start with, or slightly elevated blood pressure to start with. There is a lack of studies on people with high baseline blood pressure, but it seems likely that their blood pressure would also decrease with Ozempic.

Blood pressure reduction does seem to correlate with weight loss; however, there also seem to be some other, as yet unknown, non-weight loss mechanisms also contributing to the weight loss.

Older adults may be more susceptible to these blood pressure decreases because they are more susceptible to orthostatic hypotension – that is the sudden drop in blood pressure when standing up from sitting or lying down

Summary of Research

Across the Sustain 1-5 trials (n=3,918), greater reductions in systolic BP were related to greater weight loss. However, it also appeared that other, unknown weight loss mechanisms were also contributing to weight loss.

  • An average decrease in SBP of 2.6 to 5.1 mmHg and 2.7 to 7.3 mmHg with semaglutide 0.5 and 1.0 mg, respectively, vs −1.0 to −2.3 mmHg with comparators was reported in participants who had a baseline BP or 128.8–134.8 mmHg).
  • In the >4.0 kg WL category, the mean change in SBP was −3.0 to −6.8 and −4.4 to −9.3 mmHg with semaglutide 0.5 and 1.0 mg, respectively, vs −4.0 to +1.1 mmHg with comparators.
  • In the 0–4.0 kg WL category, the mean change in SBP was −2.0 to −4.8 mmHg and −0.7 to −5.2 mmHg with semaglutide 0.5 and 1.0 mg, respectively, vs -2.1 to -4.2 mmHg with comparators.
  • For subjects with no WL/BW gain, the mean change in SBP was −1.5 to +1.5 mmHg and −5.4 to +1.0 mmHg with semaglutide 0.5 and 1.0 mg, respectively, vs −1.0 to +1.1 mmHg with comparators.

An overall decrease in blood pressure was reported in a review of 6 high-quality RCTS (n=4744) that compared semaglutide to a placebo (an inactive treatment) (Kennedy, 2023). The mean BP before initiation of semaglutide was in the normotensive range (usually quoted as 115-120/70-75 mmHg), and most participants were female and white. Studies ranged in length from 48 to 104 weeks.

Related Questions

References
  • Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2023; 12(3):772. https://doi.org/10.3390/jcm12030772
  • Warren, M., Chaykin, L., Trachtenbarg, D., Nayak, G., Wijayasinghe, N., & Cariou, B. (2018). Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: A pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism, 20(9), 2291–2297. https://doi.org/10.1111/dom.13331
  • S Bain, M Davies, F K Knop, H Vrazic, T V Skjoth, I Lingvay, P1878.Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5, European Heart Journal, Volume 39, Issue suppl_1, August 2018, ehy565.P1878, https://doi.org/10.1093/eurheartj/ehy565.P1878

Read next

Related medical questions

Drug information

Related support groups